Ignite Creation Date:
2025-12-25 @ 5:06 AM
Ignite Modification Date:
2026-03-13 @ 6:29 AM
Study NCT ID:
NCT03135327
Status:
RECRUITING
Last Update Posted:
2025-08-12
First Post:
2017-04-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Clinical Applications of Advanced Ophthalmic Imaging
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009103', 'term': 'Multiple Sclerosis'}, {'id': 'D015352', 'term': 'Dry Eye Syndromes'}, {'id': 'D003930', 'term': 'Diabetic Retinopathy'}, {'id': 'D011305', 'term': 'Presbyopia'}, {'id': 'D009216', 'term': 'Myopia'}, {'id': 'D003704', 'term': 'Dementia'}], 'ancestors': [{'id': 'D020278', 'term': 'Demyelinating Autoimmune Diseases, CNS'}, {'id': 'D020274', 'term': 'Autoimmune Diseases of the Nervous System'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D003711', 'term': 'Demyelinating Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D007766', 'term': 'Lacrimal Apparatus Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}, {'id': 'D012164', 'term': 'Retinal Diseases'}, {'id': 'D003925', 'term': 'Diabetic Angiopathies'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D048909', 'term': 'Diabetes Complications'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D012030', 'term': 'Refractive Errors'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000711993', 'term': 'Ocufolin'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'SUPPORTIVE_CARE', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 5000}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2007-01-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-08', 'completionDateStruct': {'date': '2029-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-08-11', 'studyFirstSubmitDate': '2017-04-24', 'studyFirstSubmitQcDate': '2017-04-28', 'lastUpdatePostDateStruct': {'date': '2025-08-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-05-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Retinal microstructure using OCT.', 'timeFrame': 'up to 2 years', 'description': 'Optical coherence tomography is used to measure the thickness of intraretinal layers. The measurement is in micrometer.'}, {'measure': 'Retinal vasculature by optical coherence tomography angiography (OCTA)', 'timeFrame': 'up to 2 years', 'description': 'Retinal vascular network density in percentage.'}, {'measure': 'Conjunctival vasculature by functional slit-lamp (FSLB)', 'timeFrame': 'up to 2 years', 'description': 'Conjunctival vascular network density in percentage.'}, {'measure': 'Corneal epithelial thickness', 'timeFrame': 'up to 2 years', 'description': 'Measured in micrometers using ultra high resolution OCT'}, {'measure': 'Tear film thickness', 'timeFrame': 'up to 2 years', 'description': 'Measured in micrometers using ultra high resolution OCT'}], 'secondaryOutcomes': [{'measure': 'Retinal blood flow velocity by retinal function imager (RFI)', 'timeFrame': 'up to 2 years', 'description': 'Retinal blood flow velocity in mm/s'}, {'measure': 'Conjunctival blood flow velocity by functional slit-lamp (FSLB)', 'timeFrame': 'up to 2 years', 'description': 'Conjunctival blood flow velocity in mm/s'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Multiple Sclerosis', 'Dry Eye Syndromes', 'Diabetic Retinopathy', 'Presbyopia', 'Myopia', 'Dementia']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls.\n\nThere are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '99 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Observational Phase 1 Group\n\nInclusion Criteria:\n\n1. Self-reported normal healthy subjects;\n2. Clinical diagnosis of Alzheimer's Disease, mild cognitive impairment, multiple sclerosis, dry eye, myopia, diabetics and stroke;\n3. Who can keep the eye open for imaging.\n\nExclusion Criteria:\n\n1. who can not read and sign the ICF;\n2. who can not receiving ophthalmic imaging;\n3. who cannot tolerate bright light during imaging.\n\nInterventional Phase 2 Group:\n\nInclusion criteria\n\nThe participant will be eligible for entry in the study if s/he:\n\n1. Is at least 18 years old and has full legal capacity to volunteer;\n2. Has read and signed the IRB Informed Consent Document;\n3. Is willing and able to follow participant instructions;\n4. Has clear corneas and crystalline lens;\n5. Initial visual acuities were 20/80 or better;\n6. MTHFR C677TT homozygous, or MTHFR C677T/A1298C compound heterozygous with mild to moderate micro-aneurismal vascular retinopathy disease;\n7. Hemoglobin A1c is 10 or less;\n8. Normotensive with or without medications;\n9. Without retinal capillary dropout or macular edema;\n10. Blood homocysteine \\> 9.\n\nExclusion criteria\n\nThe subjects will be ineligible for entry into the study if s/he:\n\n1. Has an active ocular disease;\n2. Has had surgery or an eye injury within 6 months."}, 'identificationModule': {'nctId': 'NCT03135327', 'briefTitle': 'Clinical Applications of Advanced Ophthalmic Imaging', 'organization': {'class': 'OTHER', 'fullName': 'University of Miami'}, 'officialTitle': 'Clinical Applications of Advanced Ophthalmic Imaging', 'orgStudyIdInfo': {'id': '20070492'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Interventional Phase - Ocufolin Group', 'description': 'Participants in this group will receive the Ocufolin medical food for 6 months.', 'interventionNames': ['Dietary Supplement: Ocufolin']}, {'type': 'NO_INTERVENTION', 'label': 'Observational Phase Group', 'description': 'Participants in this group will be studied and followed up for 1-2 years.'}], 'interventions': [{'name': 'Ocufolin', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.', 'armGroupLabels': ['Interventional Phase - Ocufolin Group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '33136', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jianhua Wang, MD, PHD', 'role': 'CONTACT', 'email': 'jwang3@med.miami.edu', 'phone': '305-482-5010'}, {'name': 'Jianhua Wang, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Bascom Palmer Eye Institute', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}], 'centralContacts': [{'name': 'Jianhua Wang, MD, PhD', 'role': 'CONTACT', 'email': 'jwang3@med.miami.edu', 'phone': '3054825010'}], 'overallOfficials': [{'name': 'Jianhua Wang, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Bascom Palmer Eye Institute, University of Miami, Miami, FL'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Miami', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Jianhua (Jay) Wang, MD, PhD', 'investigatorAffiliation': 'University of Miami'}}}}